Stock Report

All about this stock under one free report Last Updated: 04-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

ASLAN Pharmaceuticals - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$0.60

up-down-arrow $-- (--%)

As on 16-Aug-2024 09:30EDT

Market cap

info icon

$2 Mln

Revenue (TTM)

info icon

$12 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- 0.00 -- 31.95
EBIT -- 48.65 59.18 -2.50 7.05
Net Profit 26.59 48.10 38.99 -341.26 -231.27
EPS -43,144.72 58.78 69.97 9.24 10.73
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -381.98-767.99-184.02-364.46-399.49
Net Margin info ---1,568.85-291.89----
Return on equity info 497.42292.45--1,796.92-156.49
Return on Capital info -98.84-62.49---148.58-76.49
Return on Assets info -77.28-89.23-56.43-103.06-66.00
Debt to Equity (x) info -----1.08-2.024.50

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
-148.58
-76.49
-71.45
-6.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
1,796.92
-156.49
-148.17
295.23
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-56.43

Lower than Peers by 25.45

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-56.43
-103.06
-66.00
-62.77
-90.82
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-184.02

Lower than Peers by 100.40

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-184.02
-364.46
-399.49
--
--
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-291.89

Lower than Peers by 199.22

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-291.89
-368.50
-428.19
--
--
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
--
--
--
-1.00
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

59.18

Higher than Peers by 59.98

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
59.18
8.77
-48.33
-101.72
65.32
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

38.99

Higher than Peers by 46.29

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
38.99
13.94
-48.04
-93.84
61.95
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

69.97

Higher than Peers by 55.32

Year on year growth in earnings per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
69.97
1.00
-0.48
-0.43
-5.24
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-244.26

Lower than Peers by 234.08

Year on year growth in book value per share

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-244.26
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

-1.08

--

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-1.08
-2.02
4.50
0.54
-1.84
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-0.41

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-0.41
-0.15
0.95
0.00
-0.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.05

Lower than Peers by 4.76

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
1.05
1.84
2.63
14.75
1.45
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.05

Lower than Peers by 4.65

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
1.05
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-7.91

Lower than Peers by 5.82

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-7.91
-10.11
-13.04
-17.37
-12.84
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

1.43

Lower than Peers by 17.71

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
1.43
1.43
--
--
--
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.19

Higher than Peers by 0.13

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
0.19
0.28
0.15
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
5.22
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
10,849.14
8,753.44
3,517.82
2,570.73
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
-5.19
0.00
-0.02
-0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.14

Lower than Peers by 3.04

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
2.14
-17.28
0.02
0.01
-0.07
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.35

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
-0.35
-5.42
0.40
1.83
-0.35
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

2

Lower than Peers by 144

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
ASLAN Pharmaceuticals - ADR
2
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...